Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/05/25
Amgen Beat Fourth-Quarter Expectations. So, Why Did Shares Tumble?Investors Business Daily • 02/04/25
These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025The Motley Fool • 02/04/25
The Dow Jones Industrials Are Winning 2025: 4 Highest-Yielding Dogs of the Dow Are Steals24/7 Wall Street • 02/03/25
Curious about Amgen (AMGN) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 01/31/25
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024The Motley Fool • 01/25/25
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?The Motley Fool • 01/21/25
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal CancerZacks Investment Research • 01/20/25
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 01/17/25
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCERPRNewsWire • 01/17/25
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)Seeking Alpha • 01/14/25